Zynex (ZYXI) Stock Price, News & Analysis

Written before these shares stopped trading.

Zynex, Inc. (NASDAQ: ZYXI) is a medical technology company that develops, manufactures, markets, and sells non-invasive medical devices. According to company disclosures, Zynex focuses on devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. The company was founded in 1996 and is incorporated in Nevada.

Zynex describes itself as specializing in the manufacture and sale of non-invasive medical devices that are intended to improve the quality of life for patients suffering from debilitating pain and illness. Its activities include developing and commercializing devices for pain management and rehabilitation and building a portfolio of monitoring systems for hospital settings, including fluid monitoring, sepsis-related monitoring, and laser-based pulse oximetry.

The company has historically operated through subsidiaries focused on different aspects of its medical technology offerings. Earlier descriptions note that Zynex has engineered, manufactured, and marketed neuro-diagnostics, stroke rehabilitation, pain management, and cardiac monitoring devices. One subsidiary, Zynex Medical, has been described as a provider of electrotherapy products for home use. Another, Zynex Monitoring Solutions, has focused on cardiac and patient monitoring products for hospitals, and Zynex NeuroDiagnostics has developed devices for EMG and EEG diagnostic applications within neurology disciplines.

In more recent disclosures, Zynex emphasizes its portfolio of medical devices used for pain management and rehabilitation, together with non-invasive monitoring systems designed for hospital environments. These include systems related to fluid status, sepsis, and laser-based pulse oximetry. The company has also reported submitting its NiCO laser pulse oximeter for U.S. Food and Drug Administration 510(k) review and later decided to seek a commercialization partner for that product through its Zynex Monitoring Solutions subsidiary.

Business focus and operating context

Zynex’s core business revolves around non-invasive devices that are used in clinical and home settings. Its pain management and rehabilitation devices are described as helping patients manage debilitating pain and support recovery. Earlier company descriptions state that Zynex Medical’s electrotherapy product line is fully developed, cleared by regulators such as the FDA and CE authorities, and commercially sold, with a stated mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or chronic pain.

On the monitoring side, Zynex has invested in technologies for cardiac and patient monitoring in hospitals, including multi-parameter and laser-based pulse oximetry. Through Zynex Monitoring Solutions, the company has developed monitoring products and, as disclosed in SEC filings, has adjusted its strategy by seeking third-party commercialization partners for certain monitoring technologies, such as the NiCO CO-oximeter, rather than commercializing them independently.

Corporate structure and regulatory status

Zynex, Inc. is a Nevada corporation with its principal executive offices located in Englewood, Colorado (city and state only). Its common stock has been listed on The Nasdaq Stock Market LLC under the ticker symbol ZYXI. In December 2025, the company and certain subsidiaries filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. These Chapter 11 cases are intended to support a court-supervised financial restructuring.

As disclosed in a Form 8-K, the Chapter 11 filings triggered an event of default under Zynex’s 5.00% Convertible Senior Notes due 2026. The company entered into a restructuring support agreement with certain holders of these notes and agreed to a debtor-in-possession financing facility. The company has indicated that it expects its equity holders to experience a significant loss on their investment if the contemplated restructuring transactions are implemented and has cautioned that trading in its securities during the Chapter 11 process is highly speculative.

Also in December 2025, Zynex received a written notice from The Nasdaq Stock Market stating that Nasdaq had determined to delist the company’s common stock as a result of the Chapter 11 cases, pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1. Nasdaq advised that trading in the company’s common stock would be suspended and that a Form 25-NSE would be filed with the SEC to effect the delisting. Zynex reported that it did not intend to appeal this determination and anticipated that, following suspension from Nasdaq, its common stock would commence trading on a market operated by OTC Markets Group, although no assurance was provided regarding future trading activity.

Financial condition and restructuring efforts

In 2025, Zynex reported significant declines in revenue and a shift from net income to net losses, driven in part by a temporary payment suspension from its largest insurance customer, Tricare, as well as payer policy changes, prepayment reviews, and workforce reductions. The company has disclosed substantial non-cash impairment charges, particularly related to goodwill, definite-lived intangible assets, and certain fixed assets associated with Zynex Monitoring Solutions.

In a Form 12b-25 notification of late filing for its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, Zynex stated that it anticipated disclosing substantial doubt about its ability to continue as a going concern, citing insufficient cash resources to support planned operations for at least 12 months from the expected issuance date of the financial statements. The company has engaged financial advisors to evaluate strategic alternatives, including capital raising, recapitalization, and restructuring strategies, and has formed a special committee of its board of directors to oversee this process.

Leadership and governance

In 2025, Zynex reported several changes in its leadership and board composition. The company announced the arrival of a new chief executive officer and the appointment of new leaders in key roles, including a chief financial officer and a chief legal officer. It also appointed an experienced medical device industry executive, Bret Wise, to its board of directors and as chair of the audit committee. These changes were described as part of efforts to refocus the company’s mission and vision around patient and customer outcomes, with an emphasis on integrity and compliance.

Company history and evolution

Since its founding in 1996, Zynex has evolved from a focus on electrotherapy and neuro-diagnostic devices to a broader portfolio that includes pain management, rehabilitation, and hospital-based monitoring systems. Earlier descriptions highlight three main subsidiary areas: Zynex Medical (electrotherapy products for home use), Zynex Monitoring Solutions (cardiac and patient monitoring products for hospitals), and Zynex NeuroDiagnostics (EMG and EEG diagnostic devices for neurology). Over time, the company has continued to develop and adjust its product and commercialization strategies, including pursuing regulatory clearances and exploring partnerships for certain technologies.